Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer

Cancer Gene Therapy

Volumn 3, Issue 3, 1996, Pages 168-174

  Xing, Xiangming ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gene therapy; HER 2 neu; Liposome; Mutant SV40 large T; Ovarian cancer

Indexed keywords

DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOSOME; PRIMER DNA; RECOMBINANT PROTEIN; VIRUS T ANTIGEN;

ANIMAL; ARTICLE; BIOSYNTHESIS; DISEASE FREE SURVIVAL; FEMALE; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; MOUSE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; RAT; SIMIAN VIRUS 40; SURVIVAL RATE; TIME;

ANIMALS; ANTIGENS, VIRAL, TUMOR; DISEASE-FREE SURVIVAL; DNA PRIMERS; DRUG CARRIERS; FEMALE; GENE THERAPY; HUMANS; LIPOSOMES; MICE; MICE, NUDE; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); RATS; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; SIMIAN VIRUS 40; SURVIVAL RATE; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 0030138110     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (1)

1. Kraus MH, Popescu NC, Ambaugh SC, King CR. Over-expression of the EOF receptor-related proto-oncogene erbE-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987;6:605-610.